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Introduction
Cervical cancer is the third most common cancer in women (8%). It is formed 
in tissues of the cervix, which connects the uterus and vagina. More than 
70% of cervical cancers are caused by Human Papilloma Virus (HPV) infec-
tions. Usually, this cancer grows slowly and with surgery it is eradicated. 
However, due to the latent HPV infections there are many cases of relapse.
HPV has developed multiple strategies to evade immune system and to per-
sist in the host cell. It is specialist in transforming normal cells into immortal 
cells, which is one of the main features of cancer cells. At this point the regu-
lation of telomeres and telomerase by HPV acquires an important role.  
Thanks to the great variety of mechanisms that viruses use to infect cells, 
they are becoming a great tool to treat cervical cancer in order to avoid cases 
of relapse. In addition, those engineered viruses can control cell immortality.
In summary, viruses play a dual role of cell immortality in cervical cancer. 
Then, the main goals of this review are:
(i) To explain the mechanisms of action by which HPV induces cell immortali-
ty in cervical cancer.
(ii) To address the importance of the virus as a treatment of cervical cancer 
through the control of cell immortality.
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Conclusions
HPV-16 subtype is included in the high risk level, concre-
tely; it is responsible of 50% of cervical cancers. 
HPV-16 gene encodes some viral proteins. The most im-
portant oncoproteins are E6 and E7, which can deregulate 
cell cycle due to the lost of viral protein E2 that regulates 
these oncoproteins. 
There are two main pathways that become modified: E6 
oncoprotein with E6AP (ubiquitin ligase) can block TP53 
pathway, and E7 oncoprotein can block pRB pathway. In 
both cases, this block is mediated by different mechanisms 
resulting in a high cell proliferation. 
Telomerase
In somatic cells there is not telomerase activity but HPV can activate it, usually, by the 
transcription of telomerase catalytic subunit (hTERT). This fact is accompanied by cell 
immortality and chromosome instability.
- Knowing the different action mechanisms of 
HPV on the expression of telomerase, it would be 
great to enhance modified viruses to block these 
pathways. 
- Apply the use of OBP-301 in cervical cancer in 
order to block telomerase expression and induce 
cell death.
(i) Cell immortality is associated with telomerase activation in cervical cancer. This review offers a global 
vision of the different mechanisms that HPV uses to control telomerase expression, usually, through hTERT 
subunit.
 
(ii) With some improvements, telomelysin (OBP-301) could allow scientists to control cell immortality in order 
to reduce tumour growth. Additionally, the use of OBP-301 would be a good therapy since it appears to en-
hance the immune response of the patient against the tumour. 
Future approaches
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Discussion
Oncolytic virotherapy uses virus properties to 
destroy cancer cells. Best construct to the date to 
control cell immortality is telomelysin. It derives 
from an adenovirus (Ad5) and is regulated by hTERT 
expression. This construct induces death only in 
those cells that express hTERT subunit of telomerase. 
Telomelysin remains to be tested in cervical cancer 
but it has been demonstrated that reduces tumour 
size controlling cell immortality.
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Both mechanisms result in increase of 
telomerase stability and expression.  
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HPV monitors cell immortality through hTERT regulation. It can activate telomerase expression at di-
fferent levels (A, B, C and D). In addition, HPV may down regulate telomerase activation by E2. 
A balance between negative and positive regulation ways exists for viruses which require a latent infection. 
Activated telomerase ensures that infected cells can proliferate and avoid apoptosis. However, repression 
could prevent an immune response or create a state of transient genetic instability. The reason of why and 
when each mechanism is actuating remains unclear.  
*Could be a disadvantatge in case of readministration.
HPV oncoproteins alter cell cycle checkpoints
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